TBI Rehabilitation and Activation in Veterans
This trial will evaluate the impact of a multicomponent program (TBI Rehabilitation and Activation in Veterans; TRAIN-Vets) on improving cognitive function over an 8-month trial period in older Veterans with traumatic brain injury (TBI). Older Veterans with a history of TBI and subjective cognitive complaints will be e
| Condition(s) | Traumatic Brain Injury |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This trial will evaluate the impact of a multicomponent program (TBI Rehabilitation and Activation in Veterans; TRAIN-Vets) on improving cognitive function over an 8-month trial period in older Veterans with traumatic brain injury (TBI). Older Veterans with a history of TBI and subjective cognitive complaints will be enrolled and randomly assign to either the TRAIN-Vets intervention (consisting of aquatic-based exercise training, cognitive training, and lifestyle coaching) or the Health Education Control, where they will receive educational materials about brain health and healthy lifestyles. |
| Who can participate | Inclusion Criteria: * Veteran, age 50-89 years * History (more than 6 months post injury) of mild or moderate TBI defined by the Ohio State University TBI Identification Method and DOD/VA Clinical Practice Guidelines for Definition of TBI * Sufficient vision and hearing to allow cognitive testing * Willingness to participate in water-based exercise program + cognitive training program for eight months * Approval of primary medical provider to participate in a water-based exercise program * Subjective cognitive complaints as evidenced by self-report * English proficiency to allow for cognitive testing * Internet connected device to participate in testing and cognitive training Exclusion Criteria: * Current severe and unstable psychiatric disorder * Diagnosis of dementia, Montreal Cognitive |
| Ages | 50 Years to 89 Years |
| Sex | All |
| Lead sponsor | Northern California Institute of Research and Education |
| Locations | Palo Alto, California, United States; San Francisco, California, United States |
| Start date | 2025-05-12 |
| NCT ID | NCT06562127 |
| Official listing | https://clinicaltrials.gov/study/NCT06562127 |